In this post hoc analysis, we assessed romosozumab efficacy and safety in European
patients enrolled in FRAME. Romosozumab treatment through 12 months, followed by denosumab
for a further 24 months, resulted in early and sustained risk reduction for major
fracture categories, associated with large gains in bone mineral density.
